Harvard Bioscience, Inc. (NASDAQ:HBIO) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 1,234,762 shares, an increase of 36.0% from the January 15th total of 907,584 shares. Based on an average daily trading volume, of 179,638 shares, the days-to-cover ratio is currently 6.9 days. Currently, 3.8% of the shares of the stock are sold short.

Shares of HBIO opened at $3.66 on Thursday. The company has a quick ratio of 1.49, a current ratio of 2.83 and a debt-to-equity ratio of 0.73. Harvard Bioscience has a 52-week low of $2.75 and a 52-week high of $6.70. The firm has a market capitalization of $136.87 million, a price-to-earnings ratio of 73.20 and a beta of 1.38.

Separately, ValuEngine downgraded Harvard Bioscience from a “buy” rating to a “hold” rating in a research report on Tuesday, November 13th.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC raised its position in Harvard Bioscience by 5.5% in the 4th quarter. Geode Capital Management LLC now owns 352,825 shares of the medical instruments supplier’s stock valued at $1,121,000 after purchasing an additional 18,372 shares during the last quarter. Alambic Investment Management L.P. raised its position in Harvard Bioscience by 415.8% in the 4th quarter. Alambic Investment Management L.P. now owns 135,599 shares of the medical instruments supplier’s stock valued at $431,000 after purchasing an additional 109,312 shares during the last quarter. GSA Capital Partners LLP raised its position in Harvard Bioscience by 5.3% in the 4th quarter. GSA Capital Partners LLP now owns 191,657 shares of the medical instruments supplier’s stock valued at $609,000 after purchasing an additional 9,600 shares during the last quarter. Royce & Associates LP raised its position in Harvard Bioscience by 8.2% in the 4th quarter. Royce & Associates LP now owns 1,730,200 shares of the medical instruments supplier’s stock valued at $5,502,000 after purchasing an additional 130,500 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in Harvard Bioscience by 7.8% in the 4th quarter. Bank of New York Mellon Corp now owns 110,661 shares of the medical instruments supplier’s stock valued at $352,000 after purchasing an additional 8,013 shares during the last quarter. Hedge funds and other institutional investors own 74.34% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Harvard Bioscience, Inc. (HBIO) Short Interest Up 36.0% in January” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.watchlistnews.com/harvard-bioscience-inc-hbio-short-interest-up-36-0-in-january/2819032.html.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names.

Read More: Do Tariffs Work?

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.